StockNews.com began coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Free Report) in a research report report published on Monday. The firm issued a hold rating on the biotechnology company’s stock.
Nabriva Therapeutics Stock Performance
The company has a market cap of $45.46 million, a P/E ratio of -0.07 and a beta of 1.53. Nabriva Therapeutics has a 52-week low of $1.22 and a 52-week high of $8.45. The company has a debt-to-equity ratio of 0.12, a quick ratio of 0.52 and a current ratio of 0.85.
About Nabriva Therapeutics
Further Reading
- Five stocks we like better than Nabriva Therapeutics
- 3 Monster Growth Stocks to Buy Now
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
- How to invest in marijuana stocks in 7 steps
- How the Fed’s Rate Cut Could Supercharge These 3 ETFs
- What is MarketRank™? How to Use it
- Microsoft Stock: 3 Reasons It’s Ready to Crush Q4
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.